BIOQ logo

BioqualOTCPK:BIOQ Stock Report

Market Cap US$38.6m
Share Price
US$43.19
My Fair Value
AN
AnalystConsensusTarget
US$152
71.6% undervalued intrinsic discount
1Y-40.4%
7D0%
Portfolio Value
View

Bioqual, Inc.

OTCPK:BIOQ Stock Report

Market Cap: US$38.6m

Bioqual (BIOQ) Stock Overview

Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. More details

BIOQ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends1/6

BIOQ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Bioqual, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bioqual
Historical stock prices
Current Share PriceUS$43.19
52 Week HighUS$72.50
52 Week LowUS$43.19
Beta-0.0088
1 Month Change-2.40%
3 Month Changen/a
1 Year Change-40.43%
3 Year Change-33.55%
5 Year Change-34.56%
Change since IPO14,296.09%

Recent News & Updates

Recent updates

Shareholder Returns

BIOQUS Life SciencesUS Market
7D0%7.9%1.7%
1Y-40.4%-19.5%17.7%

Return vs Industry: BIOQ underperformed the US Life Sciences industry which returned -19.5% over the past year.

Return vs Market: BIOQ underperformed the US Market which returned 17.7% over the past year.

Price Volatility

Is BIOQ's price volatile compared to industry and market?
BIOQ volatility
BIOQ Average Weekly Movementn/a
Life Sciences Industry Average Movement9.0%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: BIOQ's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981n/an/awww.bioqual.com

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.

Bioqual, Inc. Fundamentals Summary

How do Bioqual's earnings and revenue compare to its market cap?
BIOQ fundamental statistics
Market capUS$38.63m
Earnings (TTM)-US$2.13m
Revenue (TTM)US$49.00m
0.8x
P/S Ratio
-18.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOQ income statement (TTM)
RevenueUS$49.00m
Cost of RevenueUS$53.37m
Gross Profit-US$4.37m
Other Expenses-US$2.25m
Earnings-US$2.13m

Last Reported Earnings

Feb 28, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.38
Gross Margin-8.93%
Net Profit Margin-4.34%
Debt/Equity Ratio0%

How did BIOQ perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
-21%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/24 16:15
End of Day Share Price 2025/07/10 00:00
Earnings2025/02/28
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bioqual, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.